Literature DB >> 8453049

Presence of cannabinoid binding sites in the brain from early postnatal ages.

F Rodríguez de Fonseca1, J A Ramos, A Bonnin, J J Fernández-Ruiz.   

Abstract

The present study demonstrates the presence of cannabinoid receptors in the brain from early postnatal ages. Specific and saturable binding was observed in the forebrain and remaining brain from early postnatal ages (2 and 5 days after birth). Female neonate forebrain exhibited a higher receptor density at 2 days after birth than males, but this trend was inverted at 5 days. From postnatal day 10, the receptors could be measured in more defined brain areas, i.e. the striatum, limbic forebrain and ventral mesencephalon. The ontogeny of the receptors in these three areas was relatively similar, exhibiting a progressive increase which maximised on days 30 or 40 and then subsequently decreased to adult values. Subtle sexual dimorphism was found in the striatum and ventral mesencephalon but not the limbic forebrain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8453049     DOI: 10.1097/00001756-199302000-00005

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  90 in total

1.  Pretreatment with Δ9-tetrahydrocannabinol (THC) increases cocaine-stimulated activity in adolescent but not adult male rats.

Authors:  Diana Dow-Edwards; Sari Izenwasser
Journal:  Pharmacol Biochem Behav       Date:  2011-09-17       Impact factor: 3.533

Review 2.  Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?

Authors:  Rebecca M Craft; Julie A Marusich; Jenny L Wiley
Journal:  Life Sci       Date:  2012-06-20       Impact factor: 5.037

3.  Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice.

Authors:  Abigail E Agoglia; Sarah E Holstein; Vallari R Eastman; Clyde W Hodge
Journal:  Pharmacol Biochem Behav       Date:  2016-01-19       Impact factor: 3.533

4.  Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion.

Authors:  M López-Gallardo; A B López-Rodríguez; Á Llorente-Berzal; D Rotllant; K Mackie; A Armario; R Nadal; M-P Viveros
Journal:  Neuroscience       Date:  2011-10-06       Impact factor: 3.590

Review 5.  Neurobiology of the adolescent brain and behavior: implications for substance use disorders.

Authors:  B J Casey; Rebecca M Jones
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-10-08       Impact factor: 8.829

Review 6.  Neurobiological processes in adolescent addictive disorders.

Authors:  Ty S Schepis; Bryon Adinoff; Uma Rao
Journal:  Am J Addict       Date:  2008 Jan-Feb

7.  Adolescent Δ(9)-Tetrahydrocannabinol Exposure Alters WIN55,212-2 Self-Administration in Adult Rats.

Authors:  Maria Scherma; Christian Dessì; Anna Lisa Muntoni; Salvatore Lecca; Valentina Satta; Antonio Luchicchi; Marco Pistis; Leigh V Panlilio; Liana Fattore; Steven R Goldberg; Walter Fratta; Paola Fadda
Journal:  Neuropsychopharmacology       Date:  2015-09-21       Impact factor: 7.853

8.  Sex-dimorphic psychomotor activation after perinatal exposure to (-)-delta 9-tetrahydrocannabinol. An ontogenic study in Wistar rats.

Authors:  M Navarro; P Rubio; F Rodríguez de Fonseca
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

Review 9.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

10.  Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats.

Authors:  Viviana Trezza; Patrizia Campolongo; Tommaso Cassano; Teresa Macheda; Pasqua Dipasquale; Maria Rosaria Carratù; Silvana Gaetani; Vincenzo Cuomo
Journal:  Psychopharmacology (Berl)       Date:  2008-05-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.